The gene therapy player survived 2022 relatively unscathed, but big tests remain.
Meanwhile, there was bad blood between cell therapy players and their investors.
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.